LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

81.73 0.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

80.94

Max

81.86

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+3.08% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

81.51

Ankstesnė uždarymo kaina

81.73

Naujienos nuotaikos

By Acuity

34%

66%

85 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-05 21:08; UTC

Įsigijimai, susijungimai, perėmimai

Meta Platforms Buys AI-Device Maker Limitless

2025-12-05 19:39; UTC

Pagrindinės rinkos jėgos

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

2025-12-05 19:17; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

2025-12-06 16:52; UTC

Įsigijimai, susijungimai, perėmimai

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

2025-12-06 10:30; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

2025-12-06 02:38; UTC

Įsigijimai, susijungimai, perėmimai

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

2025-12-05 21:59; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

2025-12-05 21:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-12-05 21:50; UTC

Įsigijimai, susijungimai, perėmimai

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

2025-12-05 21:36; UTC

Rinkos pokalbiai

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

2025-12-05 21:35; UTC

Įsigijimai, susijungimai, perėmimai

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

2025-12-05 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

2025-12-05 21:12; UTC

Rinkos pokalbiai

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

2025-12-05 21:03; UTC

Rinkos pokalbiai
Uždarbis

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

2025-12-05 21:01; UTC

Rinkos pokalbiai

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

2025-12-05 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

2025-12-05 20:43; UTC

Įsigijimai, susijungimai, perėmimai

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

2025-12-05 20:42; UTC

Įsigijimai, susijungimai, perėmimai

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

2025-12-05 20:01; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

2025-12-05 19:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-05 19:44; UTC

Rinkos pokalbiai

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

2025-12-05 19:39; UTC

Rinkos pokalbiai

Silver Climbs to a New Record High -- Market Talk

2025-12-05 19:31; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

2025-12-05 18:30; UTC

Rinkos pokalbiai

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

2025-12-05 18:28; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

2025-12-05 18:24; UTC

Įsigijimai, susijungimai, perėmimai

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

2025-12-05 18:20; UTC

Rinkos pokalbiai

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

2025-12-05 18:11; UTC

Rinkos pokalbiai

The Tale of Two Canadian Employment Indicators -- Market Talk

2025-12-05 17:48; UTC

Rinkos pokalbiai

Canadian Youth Unemployment Rate Cools -- Market Talk

2025-12-05 17:44; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

3.08% į viršų

12 mėnesių prognozė

Vidutinis 84.33 USD  3.08%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

14

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

85 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat